

Brucella Antibody IgG GENLISA® ELISA

REF : KBD130

Ver 3.3

IVD

Enzyme Immunoassay for Qualitative Determination of
Brucella Antibody IgG in human serum and plasma

IVD	For In-vitro Diagnostic Use	REF	Catalog Number
	Store At	LOT	Batch Code
	Manufactured By		Biological Risk
	Expiry Date		Consult Operating Instructions

For Invitro Diagnostic use only. Purchase does not include or carry the right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of KRISHGEN Pudgala LLP is strictly prohibited.

REF KBD130 **96 tests**

Krishgen Pudgala LLP Unit Nos#318/319, Shah & Nahar, Off Dr E Moses Road, Worli, Mumbai 400018. India.
Tel: +91-22-49198700 | email: sales@krishgenpudgala.com

Introduction:

Brucella is a gram negative coccobacilli capable of infecting a wide range of animal and man. Of the three species causing human infection, *B. melitensis* is the most pathogenic followed by *B. suis* and *B. abortus*. Brucellosis is transmitted through contaminated and untreated milk and milk products and by direct contact with infected animals (cattle, sheep, goats, pigs, camels, buffaloes, and, very recently, seals), animal carcasses, and abortion materials. Worldwide, millions of individual are at risk, especially in developing countries where the infection in animals has not been brought under control, heat treatment procedures of milk (e.g. pasteurization) are not routinely applied, and food habits such as consumption of raw milk. The incubation period of brucellosis is usually one to three weeks, but sometimes may be several months. The illness may be mild and self-limiting or severe. The disease is accompanied by continued, intermittent, or irregular fever, headache, weight loss and generalized aching and fatigue. Urogenital symptoms may dominate the clinical presentation in some patients. This method uses *B. abortus* outer membrane, which is shared by the other species. Brucella IgG and IgA antibodies persist for many years after infection. A significant increase in Brucella IgG level is in patients with symptoms of brucellosis is indicative of recent exposure. IgM antibodies are present in acute brucellosis and also found in about 33% of patients with chronic brucellosis.

Intended Use:

The Brucella Antibody IgG GENLISA® ELISA is intended for the qualitative determination of IgG class antibodies in human serum and plasma.

Principle:

Brucella Antibody IgG GENLISA® ELISA is an indirect enzyme linked immunosorbent assay for qualitative determination of IgG antibody present in the human serum and plasma. Microtiter wells are pre-coated with specific Brucella antigens. Samples and Controls are pipetted into microwells and Brucella IgG antibody present in sample binds to the antigen coated on the wells. Enzyme Conjugate antibody is pipetted and incubated to form an immune complex. After washing microwells in order to remove any non-specific binding, the substrate solution is added to microwells and color develops proportionally to the amount of Brucella IgG present in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Materials Provided:

1. Brucella antigen Coated Microtiter Plate (96 wells) - 1 no
2. Positive control - 1 ml
3. Negative control - 1 ml
4. Calibrator – 1 ml
5. Enzyme conjugate - 12 ml
6. Sample diluent - 22 ml
7. (20X) Wash Buffer – 25 ml
8. TMB Substrate - 12 ml
9. Stop Solution - 12 ml
10. Instruction Manual

Materials to be provided by the End-User:

1. Microtiter Plate Reader able to measure absorbance at 450 nm.
2. Deionized (DI) water
3. Precision single and multi-channel pipette and disposable tips.
4. Disposable pipette tips.
5. Absorbent paper.
6. Graph Paper.

Handling/Storage:

1. Store main kit components at recommended storage temperature indicated on the component label.

2. Before using, bring all components to room temperature (18-25°C). Upon assay completion return all components to appropriate storage conditions.
3. The Substrate is light-sensitive and should be protected from direct sunlight or UV sources.

Health Hazard Warnings:

1. Reagents that contain preservatives may be harmful if ingested, inhaled or absorbed through the skin.
2. To reduce the likelihood of blood-borne transmission of infectious agents, handle all serum and/or plasma in accordance with NCCLS regulations.



Specimen Collection and Handling:

Serum- Coagulate at room temperature for 10 - 20 minutes; centrifuge for 20 minutes at 2000-3000 rpm. Remove the supernatant. If precipitation appears, re-centrifuge.

Plasma- Use EDTA or citrate plasma as an anticoagulant, mix for 10 - 20 minutes; centrifuge for 15 minutes at 2000-3000 rpm. Remove the supernatant carefully. If precipitation appears, re-centrifuge.

Sample Dilution:

Prepare 1:21 dilution of test samples, by adding 10 ul of the sample to 200 ul of sample diluent. Mix well.

Reagent Preparation:

1. Allow all components to reach RT (Room Temperature) prior to use in the assay.
2. (1X) Wash Buffer Dilution: To make (1X) Wash Buffer, add 25ml of (20X) Wash Buffer to 475ml of DI water. This is the working solution.

Test Procedure:

1. All reagents should be allowed to reach room temperature before use.
2. For the reagent blank, dispense 100ul sample diluent in 1A well position.
3. Add **100 ul Calibrators, Controls & diluted Sample** in appropriate wells.
4. Seal the plate and Incubate at Room Temperature for 20 minutes.
5. Aspirate and wash plate 5 times with **(1X) Wash Buffer** and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step. All the washes should be performed similarly.
6. Add **100 ul of Enzyme Conjugate** to each well.
7. Incubate at Room Temperature for 20 minutes.
8. Repeat the Wash Step as mentioned in step 5.
9. Add **100 ul of TMB Substrate** into each well.
10. Incubate at Room Temperature for 10 minutes.
11. Add **100 ul of Stop Solution**. Read result with an ELISA reader at 450 nm within 15 minutes of stopping the reaction.

Calculation of results:

Cut off (CO) Calculation:

Cut off (CO) = **Calibrator OD x Calibrator Factor (CF)**

Note: The value of calibrator factor might vary from lot to lot.

Antibody Index Calculation:

Antibody Index: $\frac{\text{Absorbance of Sample}}{\text{Cut-off value}}$

Example of typical results:

Mean Absorbance of Calibrator = 0.8

Calibrator Factor (CF) = 0.5

Cut-off Value = $0.8 \times 0.5 = 0.400$

Positive Control OD = 1.2

Antibody Index of Positive Control = $1.2/0.4 = 3$

Patient Sample OD = 1.6

Antibody Index of Sample = 4.0

Validity of the test:

The test run may be considered valid provided the following criteria are met:

1. The O.D. of the Calibrator should be greater than 0.250.
2. The Ab index for Negative control should be less than 0.9.
3. The Ab index for Positive control should fall within the range specified that is 3.0 – 5.6

Interpretation of Results:

The following is intended as a guide to interpretation of Brucella IgG test results; each laboratory is encouraged to establish its own criteria for test interpretation based on sample populations encountered.

- <0.9 No detectable antibody to Brucella IgG by ELISA
- 0.9-1.1 Borderline positive. Follow-up testing is recommended if clinically indicated.
- >1.1 Detectable antibody to Brucella IgG By ELISA.

Limitations of the test:

1. The Test results obtained using this kit serve only as an aid to diagnosis and should be interpreted in relation to the patient's history, physical findings and other diagnostic procedures.
2. Lipemic or hemolyzed samples may cause erroneous results.

Performance Characteristics:

Sensitivity and Specificity:

92 patient sera were tested by this Brucella IgG ELISA and a reference ELISA method. 14 sera were positive and 77 were negative by both methods (99% agreement). The results are summarized below:

		Brucella IgG ELISA		
		+	-	Total
Reference ELISA Kit	+	14	0	14
	-	1	77	78
Total		15	77	92

Precision:
Intra-Assay:

Sample	No. of Relicates	Mean	SD	CV %
1	16	1.31	0.071	5.41
2	16	0.86	0.052	6.04
3	16	0.24	0.015	6.25

Inter-Assay:

Sample	No. of Relicates	Mean	SD	CV %
1	10	1.92	0.21	10.93
2	10	1.44	0.17	11.80
3	10	0.25	0.032	12.80

REFERENCES

1. Gad El-Rab MO; Kambal AM. Evaluation of a Brucella enzyme immunoassay test (ELISA) in comparison with bacteriological culture and agglutination. J Infect 1998; 36(2):197-201.
2. Mikolon AB; Gardner IA; Hietala SK; Hernandez de Anda J; Chamizo Pestana E; Hennager SG; Edmondson AJ. Evaluation of North American antibody detection tests for diagnosis of brucellosis in goats. J Clin Microbiol 1998; 36(6):1716-22.
3. Bowden RA; Cloeckaert A; Zygmunt MS; Bernard S; Dubray G. Surface exposure of outer membrane protein and lipopolysaccharide epitopes in Brucella species studied by enzyme-linked immunosorbent assay and flow cytometry. Infect Immun 1995; 63(10):3945-52.
4. Baldi PC; Miguel SE; Fossati CA; Wallach JC. Serological follow-up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of Brucella species. Clin Infect Dis 1996;22(3):446-55
5. Casao MA; Leiva J; Diaz R; Gamazo C. Anti-phosphatidylcholine antibodies in patients with brucellosis. J Med Microbiol 1998; 47(1):49-54.

Safety Precautions:

- **This kit is For In-vitro Diagnostic Use only.** Follow the working instructions carefully.
- The expiration dates stated on the kit are to be observed. The same relates to the stability stated for reagents
- Do not use or mix reagents from different lots.
- Do not use reagents from other manufacturers.
- Avoid time shift during pipetting of reagents.
- All reagents should be kept in the original shipping container.
- Some of the reagents contain small amount of sodium azide (< 0.1 % w/w) as preservative. They must not be swallowed or allowed to come into contact with skin or mucosa.
- Source materials maybe derived from human body fluids or organs used in the preparation of this kit were tested and found negative for HBsAg and HIV as well as for HCV antibodies. However, no known test guarantees the absence of such viral agents. Therefore, handle all components and all patient samples as if potentially hazardous.
- Since the kit contains potentially hazardous materials, the following precautions should be observed
 - Do not smoke, eat or drink while handling kit material
 - Always use protective gloves
 - Never pipette material by mouth
 - Wipe up spills promptly, washing the affected surface thoroughly with a decontaminant.
- In any case GLP should be applied with all general and individual regulations to the use of this kit.



LIMITED WARRANTY

Krishgen Pudgala LLP does not warrant against damages or defects arising in shipping or handling, or out of accident or improper or abnormal use of the product; against defects in products or components not manufactured by Krishgen Pudgala LLP, or against damages resulting from such non-Krishgen Pudgala LLP made products or components. Krishgen Pudgala LLP passes on to customer the warranty it received (if any) from the maker thereof of such non-Krishgen made products or components. This warranty also does not apply to product to which changes or modifications have been made or attempted by persons other than pursuant to written authorization by Krishgen Pudgala LLP.

THIS WARRANTY IS EXCLUSIVE. The sole and exclusive obligation of Krishgen Pudgala LLP shall be to repair or replace the defective product in the manner and for the period provided above. Krishgen Pudgala LLP shall not have any other obligation with respect to the products or any part thereof, whether based on contract, tort, strict liability or otherwise. Under no circumstances, whether based on this Limited Warranty or otherwise, shall Krishgen Pudgala LLP be liable for incidental, special, or consequential damages.

This Limited Warranty states the entire obligation of Krishgen Pudgala LLP with respect to the product. If any part of this Limited Warranty is determined to be void or illegal, the remainder shall remain in full force and effect.

Krishgen Pudgala LLP, 2026.

THANK YOU FOR USING KRISHGEN PRODUCT!



Krishgen Pudgala LLP

Unit No.1/2, Om Sainath Commercial Complex,
Off Mankoli-Anjur Phata Road. Village Dapode, Bhiwandi 421302.


Regulatory Status:

CE Marked	Europe
FDA registered	USA
CDSCO registered	India

SCHEMATIC ASSAY PROCEDURE

1	All reagents should be allowed to reach room temperature before use.
2	For the reagent blank, dispense 100ul sample diluent in 1A well position.
3	Add 100 ul Calibrators, Controls & diluted Sample in appropriate wells.
4	Seal the plate and Incubate at Room Temperature for 20 minutes.
5	Aspirate and wash plate 5 times with (1X) Wash Buffer and blot residual buffer by firmly tapping plate upside down on absorbent paper. Wipe of any liquid from the bottom outside of the microtiter wells as any residue can interfere in the reading step. All the washes should be performed similarly.
6	Add 100 ul of Enzyme Conjugate to each well.
7	Incubate at Room Temperature for 20 minutes.
8	Repeat the Wash Step as mentioned in step 5.
9	Add 100 ul of TMB Substrate into each well.
10	Incubate at room temperature for 10 minutes.
11	Add 100 ul of Stop Solution . Read result with an ELISA reader at 450 nm within 15 minutes stopping the reaction.

SYMBOLS KEY

	Coated Microtiter Plate (96 wells)
	Positive Control
	Negative Control
	Calibrator
	Enzyme Conjugate
	Sample Diluent
	(20X) Wash Buffer
	TMB Substrate
	Stop Solution
	Consult Instructions for Use
	Catalog Number
	Expiration Date
	Storage Temperature